Abstract
Age- and stress-induced modulations in chaperone systems result in “chaperono-deficiency” or “chaperonopulence”. Development of modulators, of chaperone function has therefore, become an emerging field in drug development and discovery. This mini-review summarizes (i) the events leading to identification of an Hsp70 family stress chaperone, mortalin, (ii) experimental evidence to its role in old age diseases and cancer, and (iii) proposes it as a chaperonotherapeutic agent. As post-translational modifications and expression changes in mortalin are being explored as a biomarker for cancer, cardiovascular diseases and neurodegeneration, we discuss here how the current tools used in studying mortalin (e.g. antibodies, peptides, ribozymes, antisense and siRNA, recombinant proteins and small molecules etc.) could be creatively applied in a clinical setting to manage stress and to treat various chaperone-based maladies or “chaperonopathies”.
Keywords: Mortalin, stress chaperone, upregulation, cancer, chaperono-therapeutic agent, aging
Protein & Peptide Letters
Title: The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Volume: 16 Issue: 5
Author(s): Custer C. Deocaris, Sunil C. Kaul and Renu Wadhwa
Affiliation:
Keywords: Mortalin, stress chaperone, upregulation, cancer, chaperono-therapeutic agent, aging
Abstract: Age- and stress-induced modulations in chaperone systems result in “chaperono-deficiency” or “chaperonopulence”. Development of modulators, of chaperone function has therefore, become an emerging field in drug development and discovery. This mini-review summarizes (i) the events leading to identification of an Hsp70 family stress chaperone, mortalin, (ii) experimental evidence to its role in old age diseases and cancer, and (iii) proposes it as a chaperonotherapeutic agent. As post-translational modifications and expression changes in mortalin are being explored as a biomarker for cancer, cardiovascular diseases and neurodegeneration, we discuss here how the current tools used in studying mortalin (e.g. antibodies, peptides, ribozymes, antisense and siRNA, recombinant proteins and small molecules etc.) could be creatively applied in a clinical setting to manage stress and to treat various chaperone-based maladies or “chaperonopathies”.
Export Options
About this article
Cite this article as:
Deocaris C. Custer, Kaul C. Sunil and Wadhwa Renu, The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent, Protein & Peptide Letters 2009; 16 (5) . https://dx.doi.org/10.2174/092986609788167770
DOI https://dx.doi.org/10.2174/092986609788167770 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Hydrophilic Modification of Au Nanoparticles on the Gold Electrode of QCM by Plasma Deposition for Biomedical Applications
Current Nanoscience Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics Anabolic Effects of Intermittent PTH on Osteoblasts
Current Molecular Pharmacology Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry The mAP-KL Algorithm Combined with Mutual Information Network Used to Screen Hub Genes in Osteosarcoma
Current Bioinformatics Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry